Stock 6891 LOCUS CELL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Locus Cell Co., Ltd.

Equities

6891

TW0006891005

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 23:00:00 23/05/2024 BST 		5-day change 1st Jan Change
30.85 TWD -0.32% Intraday chart for Locus Cell Co., Ltd. +1.82% -2.06%
05-10 Locus Cell Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-15 Locus Cell Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 7,230 6,300
Enterprise Value (EV) 1 5,425 4,669
P/E ratio -134 x -65 x
Yield - -
Capitalization / Revenue 12,050,000,000 x 15,517,241,379 x
EV / Revenue 9,042,435,000 x 11,499,236,453 x
EV / EBITDA -59,455,152 x -34,207,619 x
EV / FCF -81,081,407 x -30,673,092 x
FCF Yield -0% -0%
Price to Book 3.78 x 3.45 x
Nbr of stocks (in thousands) 200,000 200,000
Reference price 2 36.15 31.50
Announcement Date 25/04/23 15/04/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales - - 0.6 0.406
EBITDA - -33.36 -91.25 -136.5
EBIT 1 -0.252 -33.52 -92.14 -140.4
Operating Margin - - -15,357.17% -34,588.18%
Earnings before Tax (EBT) 1 -0.252 -34.52 -53.48 -96.89
Net income 1 -0.252 -34.52 -53.48 -96.89
Net margin - - -8,913% -23,865.52%
EPS 2 -2.520 -0.2726 -0.2700 -0.4845
Free Cash Flow - -22.5 -66.91 -152.2
FCF margin - - -11,152.29% -37,489.66%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 31/03/22 31/03/22 25/04/23 15/04/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - - - -
Net Cash position 1 1 1,890 1,805 1,631
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - -22.5 -66.9 -152
ROE (net income / shareholders' equity) - -3.51% -2.76% -5.18%
ROA (Net income/ Total Assets) - -2.06% -2.85% -4.48%
Assets 1 - 1,678 1,875 2,162
Book Value Per Share 2 9.370 9.830 9.570 9.130
Cash Flow per Share 2 10.00 2.790 8.920 8.540
Capex - 1.46 24.2 83.1
Capex / Sales - - 4,025.33% 20,462.07%
Announcement Date 31/03/22 31/03/22 25/04/23 15/04/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LOCUS CELL CO., LTD. Stock Locus Cell Co., Ltd.
-2.06% 192M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+12.30% 116B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.15% 106B
BIONTECH SE Stock BioNTech SE
-8.14% 23.89B
ARGENX SE Stock argenx SE
-1.69% 21.58B
GENMAB A/S Stock Genmab A/S
-10.60% 18.96B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.25% 16.96B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.33% 16.33B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.80% 14.14B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.03% 12.02B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 6891 Stock
  4. Financials Locus Cell Co., Ltd.